Granahan Investment Management LLC Has $3.49 Million Holdings in Health Catalyst, Inc. (NASDAQ:HCAT)

Granahan Investment Management LLC cut its position in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 52.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 493,364 shares of the company's stock after selling 539,119 shares during the quarter. Granahan Investment Management LLC owned approximately 0.81% of Health Catalyst worth $3,488,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Quantbot Technologies LP acquired a new stake in Health Catalyst in the 4th quarter worth $29,000. Aquatic Capital Management LLC bought a new position in Health Catalyst during the 4th quarter valued at about $63,000. Stoneridge Investment Partners LLC bought a new position in Health Catalyst during the 4th quarter valued at about $77,000. Martin Worley Group bought a new position in shares of Health Catalyst in the fourth quarter worth about $78,000. Finally, Brevan Howard Capital Management LP bought a new position in shares of Health Catalyst in the fourth quarter worth about $92,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Health Catalyst news, COO Daniel Lesueur sold 16,902 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total value of $76,397.04. Following the transaction, the chief operating officer now directly owns 216,250 shares in the company, valued at $977,450. The trade was a 7.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Linda Llewelyn sold 6,441 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $5.43, for a total transaction of $34,974.63. Following the completion of the transaction, the insider now owns 85,819 shares in the company, valued at approximately $465,997.17. This represents a 6.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,588 shares of company stock valued at $217,259. 2.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Royal Bank of Canada lowered their price target on shares of Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating for the company in a research report on Thursday, February 27th. Stifel Nicolaus boosted their price objective on shares of Health Catalyst from $5.00 to $5.50 and gave the company a "hold" rating in a report on Thursday, May 8th. Wells Fargo & Company decreased their price objective on shares of Health Catalyst from $13.00 to $10.00 and set an "overweight" rating for the company in a report on Tuesday, January 21st. Canaccord Genuity Group decreased their price objective on shares of Health Catalyst from $10.00 to $9.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, KeyCorp decreased their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an "overweight" rating for the company in a report on Wednesday, April 16th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $8.00.

Health Catalyst Stock Down 2.6%

Shares of HCAT stock traded down $0.11 during trading on Wednesday, reaching $4.18. The company's stock had a trading volume of 476,036 shares, compared to its average volume of 599,697. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The business has a fifty day moving average price of $4.13 and a 200-day moving average price of $5.87. Health Catalyst, Inc. has a one year low of $3.56 and a one year high of $9.24. The company has a market cap of $293.48 million, a price-to-earnings ratio of -3.10 and a beta of 1.56.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.